Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PTPRE | P23469 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | MYC | P01106 | 1/20 | 0.34 |
| ▸ | MAX | P61244 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1340721 | 0.87 | MAPK14 (0.39) | LPAR1AURKAAURKBPTPREMAPK14 | |
| SCHEMBL1342347 | 0.86 | KDM4E (0.41) | MAPTTSHRPOLBLPAR1KDM4E | |
| SCHEMBL1341613 | 0.84 | LPAR1 (0.39) | MAPTLPAR1MAPK14MYCMAX | |
| SCHEMBL1343714 | 0.84 | LPAR1 (0.38) | MAPTLPAR1MAPK14MYCMAX | |
| SCHEMBL1342739 | 0.84 | LPAR1 (0.40) | MAPTLPAR1MAPK14MYCMAX | |
| SCHEMBL1342613 | 0.83 | KDR (0.42) | LPAR1MAPK14PKM | |
| SCHEMBL1343415 | 0.83 | IDH2 (0.38) | MAPTPOLBLPAR1MAPK14MYC | |
| SCHEMBL1342497 | 0.82 | ITGB1 (0.42) | MAPTTSHRLPAR1MAPK14MYC | |
| SCHEMBL1343242 | 0.82 | LPAR1 (0.37) | MAPTPOLBLPAR1MAPK14MYC | |
| SCHEMBL1342849 | 0.82 | LPAR1 (0.39) | MAPTPOLBLPAR1KDM4EPTPRE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | MAPT 2678/4885TSHR 2745/4885GAA 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.